Soleno Therapeutics assumed with a Buy rating, $40 target at Guggenheim

As previously reported, Guggenheim assumed coverage of Soleno Therapeutics with a Buy rating and $40 price target. DCCR is positioned as the first treatment for Prader-Willi syndrome, or PWS, with likely approval in early 2025, says the analyst, who notes that the firm’s pediatric endocrinology key opinion leader contacts see “substantial evidence of clinical effectiveness,” expect FDA approval, and frame the addressable U.S. market at about 4,500 subjects. The firm’s base case assumes deep uptake within the 4,500 patients in the U.S., with DCCR achieving probability adjusted peak sales of $800M-plus during 2030.